Eckert & Ziegler SE

Explore why Eckert & Ziegler SE’s “pick‑and‑shovel” model fuels Q4 revenue growth and a strong buy rating, offering investors a steady, low‑volatility healthcare asset.

Record‑year earnings for Eckert & Ziegler, despite a cyber‑attack, show robust growth, new oncology sales, and a reinforced cyber‑security strategy that protects future performance.

Positive Kursentwicklung von Eckert & Ziegler SE im TecDAX & SDAX – 15,55 EUR, 3,32 % Anstieg, starke Wachstumschance im Gesundheits‑Tech‑Sektor.

Explore Eckert & Ziegler’s market position, share performance and sector dynamics – insights for investors on the German radiology equipment maker.

Discover how Eckert & Ziegler SE’s 2025 earnings, 8% growth target, and November rally boost investor returns, and why the TecDAX‑listed company is a solid pick for tech‑health stocks.

Eckert & Ziegler SE, a German healthcare equipment and supplies company, is navigating a turbulent market with a strong track record, but faces challenges including currency fluctuations and industry headwinds.

Eckert & Ziegler SE’s stock price surges 2.60% to 65.15 EUR following the approval of Telix Pharmaceuticals’ Illuccix imaging agent in Germany, positioning the company for growth in the global healthcare market.

Eckert & Ziegler SE has demonstrated resilience and strategic foresight by confirming its 2025 financial projections, despite a subdued start to the year and a cyberattack, and remains a key player in the health care equipment and supplies industry.

Eckert & Ziegler SE reported steady growth in Q1 2025, with an 8% increase in revenue, despite a challenging start to the year due to a cyberattack.

Eckert & Ziegler SE, a German pharmaceutical company, has demonstrated resilience in the face of challenges, reaffirming its 2025 revenue forecast and maintaining a strong market presence despite a cyberattack and other setbacks.